Page 55, lines 24-31, amend to read as follows:

Cattle

DTH-response:

CFP10 has been tested on both *M. avium* and *M. bovis* infected animals. In *M. avium* infected (ppdA positive) animals no DTH response was measured compared to *M. bovis* (ppdB positive) infected where a significant DTH response was observed in many of the cattle. Further more blood cells isolated from cattle infected with *M. bovis* induced an *in vitro* proliferative response and release of IFN-γ after stimulation with CFP10.

IN THE CLAIMS

Please cancel Claims 1-55, without prejudice toward the further prosecution of these claims in Continuation and/or Divisional Application.

Please add the following new claims:

56. (New) A purified polypeptide, wherein said purified polypeptide is expressed by a recombinant cell host, and

wherein said recombinant cell host contains a polynucleotide,

wherein said polypeptide is encoded by said polynucleotide, and

wherein said polynucleotide is selected from the group consisting of:

a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO 1;

b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO 2, or a biologically active polynucleotide derivative of SEQ ID NO 2;

c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO 3, or a biologically active polynucleotide derivative of SEQ ID NO 3;

d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO 4;

e) a polynucleotide comprising at least 12 consecutive nucleotides of a polynucleotide selected from the group consisting of SEQ ID NO 2, SEQ ID NO 3, and SEQ ID NO 4;

f) a polynucleotide having a sequence fully complimentary to a polynucleotide selected from the group consisting of SEQ ID NO 2, SEQ ID NO 3, and SEQ ID NO 4; and

g) a polynucleotide hybridizing under stringent hybridization conditions with polynucleotide selected from the group consisting of SEQ ID NO 2, SEQ ID NO 3, and SEQ ID NO 4.

57. (New) A purified polypeptide of Claim 56 which is selected from the group consisting of:

sub D7

a) a polypeptide which comprises the amino acid sequence of SEQ ID NO 5;

b) a polypeptide comprising:

i) from amino acid in position 1 to amino acid in position 48 of SEQ ID NO 5; or

ii) from amino acid in position 60 to amino acid in position 100 of SEQ ID NO 5;

c) a polypeptide comprising at least one antigenic portion of a polypeptide a) or b).

58. (New) An oligomeric polypeptide comprising at least two units of a polypeptide according to Claim 57.

59. (New) The oligomeric polypeptide of Claim 58 comprising up to 10 units of a polypeptide according to Claim 57.

60. (New) A purified polypeptide comprising at least one antigenic portion of a polypeptide according to Claim 57.

60. (New) A purified polypeptide comprising at least one antigenic portion of a polypeptide according to Claim 57.

61. (New) The purified polypeptide according to Claim 60, wherein an antigenic portion of the polypeptide of sequence SEQ ID NO 5 is selected from the group consisting of:

a) the polypeptide of SEQ ID NO 6;

b) the polypeptide of SEQ ID NO 7;

c) the polypeptide of SEQ ID NO 8;

d) the polypeptide of SEQ ID NO 9;

e) the polypeptide of SEQ ID NO 10;

f) the polypeptide of SEQ ID NO 11;

g) the polypeptide of SEQ ID NO 12; and

h) the polypeptide of SEQ ID NO 13.

62. (New) The purified polypeptide according to Claim 60, comprising from 2 to 10 antigenic portions of the polypeptide of SEQ ID NO 5.

63. (New) A purified polypeptide or an oligomeric polypeptide according to any one of Claims 56 to 62 which is a multiple antigen peptide construct.

64. (New) A purified polypeptide or an oligomeric polypeptide according to any one of Claims 56 to 62 which comprises an additional T-epitope.

65. (New) An immunogenic composition, comprising a purified polypeptide or an oligomeric polypeptide according to any one of Claims 56 to 62.

66. (New) A composition comprising a purified polypeptide or an oligomeric polypeptide according to any one of Claims 56 to 62.

67. (New) The composition according to Claim 66, wherein said composition comprises additionally an antigenic protein from *Mycobacterium tuberculosis* or an antigenic portion of an antigenic protein from *Mycobacterium tuberculosis*.

68. (New) The composition according to Claim 67, wherein said composition comprises additionally the ESAT-6 antigenic protein or an antigenic portion of the ESAT-6 protein.

69. (New) A diagnostic method for detecting the presence of *Mycobacterium tuberculosis* in the serum of a patient, said diagnostic method comprising the steps of:

a) incubating a serum sample which may contain *Mycobacterium tuberculosis* antibodies with a purified polypeptide or an oligomeric polypeptide according to any one of Claims 56 to 62, for a time sufficient to form an antigen-antibody complex between said *Mycobacterium tuberculosis* antibodies and said purified polypeptide or oligomeric polypeptide;

b) detecting any said antigen-antibody complex formed; and

c) relating the detection of said antigen-antibody complex to the presence of *Mycobacterium tuberculosis*

70. (New) A diagnostic kit for the in vitro diagnosis of an infection by *Mycobacterium tuberculosis*, comprising the following elements:

a) a purified preparation of a purified polypeptide or an oligomeric polypeptide according to any one of Claims 56 to 62;

b) suitable reagents for detecting any antigen/antibody complexes formed, said reagents preferably carrying a label compound, or being recognized themselves by a labeled reagent;